TORIma Academy Logo TORIma Academy
Jennifer Doudna
Science

Jennifer Doudna

TORIma Academy — Biochemist / CRISPR

Jennifer Doudna

Jennifer Doudna

Jennifer Anne Doudna ( ; born February 19, 1964) is an American biochemist who has pioneered work in CRISPR gene editing, and made other fundamental…

Jennifer Anne Doudna (; born February 19, 1964) is an American biochemist renowned for her pioneering contributions to CRISPR gene editing and other foundational advancements in biochemistry and genetics. In 2020, she was jointly awarded the Nobel Prize in Chemistry with Emmanuelle Charpentier for their groundbreaking work on "the development of a method for genome editing." Currently, she holds the Li Ka Shing Chancellor's Chair Professorship across the departments of chemistry and molecular and cell biology at the University of California, Berkeley. Since 1997, she has also served as an investigator for the Howard Hughes Medical Institute.

Jennifer Anne Doudna (; born February 19, 1964) is an American biochemist who has pioneered work in CRISPR gene editing, and made other fundamental contributions in biochemistry and genetics. She received the 2020 Nobel Prize in Chemistry, with Emmanuelle Charpentier, "for the development of a method for genome editing." She is the Li Ka Shing Chancellor's Chair Professor in the department of chemistry and the department of molecular and cell biology at the University of California, Berkeley. She has been an investigator with the Howard Hughes Medical Institute since 1997.

In 2012, Doudna and Emmanuelle Charpentier collaboratively introduced the pioneering concept that CRISPR-Cas9, a bacterial enzyme system governing microbial immunity, could be harnessed for programmable genome editing. This proposition has been widely recognized as one of the most pivotal discoveries in biological history. Subsequently, Doudna has emerged as a preeminent figure in the "CRISPR revolution," distinguished by her foundational research and leadership in advancing CRISPR-mediated genome editing technologies.

Doudna's extensive accolades include the 2000 Alan T. Waterman Award, recognizing her X-ray crystallography research on ribozyme structure, and the 2015 Breakthrough Prize in Life Sciences, shared with Charpentier, for CRISPR-Cas9 genome editing technology. Further distinctions include co-receipt of the Gruber Prize in Genetics (2015), the Tang Prize (2016), the Canada Gairdner International Award (2016), and the Japan Prize (2017). In 2015, she was recognized among Time's 100 most influential individuals, and in 2023, she was inducted into the National Inventors Hall of Fame. The 2020 Nobel Prize in Chemistry was jointly conferred upon Jennifer Doudna and Emmanuelle Charpentier for their development of CRISPR-Cas9 genome editing technology, a breakthrough that has profoundly revolutionized molecular biology and offers substantial promise for the treatment of genetic disorders.

Early Life and Academic Background

Jennifer Doudna was born on February 19, 1964, in Washington, D.C., to Dorothy Jane (Williams) and Martin Kirk Doudna. Her father earned a Ph.D. in English literature from the University of Michigan, while her mother possessed a master's degree in education. At the age of seven, Doudna's family relocated to Hawaii, where her father assumed a teaching role in American literature at the University of Hawaii at Hilo. Concurrently, her mother obtained a second master's degree in Asian history from the same university and subsequently taught history at a local community college.

During her upbringing in Hilo, Hawaii, Doudna developed a profound fascination with the local flora and fauna. Her father, an avid reader of scientific literature, maintained a collection of popular science books at home. In her sixth grade, he presented her with James Watson's seminal 1968 work on the discovery of DNA structure, The Double Helix, which proved to be a significant source of inspiration. Concurrently, Doudna cultivated her interest in science and mathematics throughout her schooling.

During her tenure at Hilo High School, Doudna's scientific inclinations were significantly fostered by her 10th-grade chemistry teacher, Jeanette Wong, whom Doudna has consistently acknowledged as a pivotal figure in igniting her early scientific curiosity. Additionally, a visiting lecturer specializing in cancer cells further motivated her to consider science as a professional path. She undertook a summer research position in the laboratory of distinguished mycologist Don Hemmes at the University of Hawaii at Hilo, graduating from Hilo High School in 1981.

Doudna pursued her undergraduate studies in biochemistry at Pomona College in Claremont, California. During her freshman year, a general chemistry course led her to question her aptitude for a scientific career, prompting her to contemplate a sophomore year major change to French. Nevertheless, her French instructor advised her to persist in science. Professors Fred Grieman and Corwin Hansch, both chemists at Pomona, exerted considerable influence on her academic trajectory. Her initial scientific research was conducted in Professor Sharon Panasenko's laboratory. She was awarded her Bachelor of Arts degree in biochemistry in 1985. Subsequently, she undertook doctoral studies at Harvard Medical School, obtaining a Ph.D. in biological chemistry and molecular pharmacology in 1989. Her Ph.D. dissertation, supervised by Jack W. Szostak, focused on a system designed to enhance the efficiency of a self-replicating catalytic RNA.

Career and Research Endeavors

Following the completion of her doctoral studies, she undertook research fellowships in molecular biology at Massachusetts General Hospital and in genetics at Harvard Medical School. Between 1991 and 1994, she served as a Lucille P. Markey Postdoctoral Scholar in Biomedical Science at the University of Colorado Boulder, collaborating with Thomas Cech. As of 2025, Doudna's h-index stands at 166 according to Google Scholar and 134 according to Scopus.

Investigation into Ribozyme Structure and Function

During the initial phase of her scientific career, Doudna dedicated her efforts to elucidating the structure and biological function of RNA enzymes, known as ribozymes. While affiliated with the Szostak laboratory, Doudna successfully re-engineered the self-splicing Tetrahymena Group I catalytic intron, transforming it into a genuine catalytic ribozyme capable of replicating RNA templates. Although her primary focus involved engineering ribozymes and comprehending their fundamental mechanisms, she recognized a significant impediment in the inability to visualize these molecular processes directly. Consequently, Doudna joined Thomas Cech's laboratory at the University of Colorado Boulder with the objective of crystallizing and, for the first time, determining the three-dimensional structure of a ribozyme, thereby enabling a comparative analysis with the structures of protein-based enzymes. This project commenced in the Cech laboratory in 1991 and was concluded at Yale University in 1996. In 1994, Doudna commenced her tenure at Yale University as an assistant professor within the Department of Molecular Biophysics and Biochemistry.

X-ray Diffraction Analysis of Ribozyme Active Site Structure at Yale

While at Yale, Doudna's research group successfully crystallized and elucidated the three-dimensional structure of the catalytic core of the Tetrahymena Group I ribozyme. Their findings revealed a cluster of five magnesium ions within a specific region of the ribozyme's P4-P6 domain, establishing a hydrophobic core that facilitated the folding of the remaining structure. This structural arrangement exhibits an analogy, yet chemical distinction, to the typical hydrophobic amino acid core found in proteins. Subsequently, her group also achieved the crystallization of other ribozymes, notably the Hepatitis Delta Virus ribozyme. This foundational research in resolving large RNA structures subsequently paved the way for additional structural investigations into elements such as an internal ribosome entry site (IRES) and various protein-RNA complexes, including the signal recognition particle.

In 2000, Doudna received a promotion to the esteemed position of Henry Ford II Professor of Molecular Biophysics and Biochemistry at Yale. During the academic years 2000–2001, she concurrently served as the Robert Burns Woodward Visiting Professor of Chemistry at Harvard University.

Transition to Berkeley

In 2002, she relocated to Berkeley to join her husband, Jamie Cate, accepting a professorship in biochemistry and molecular biology. This move also granted Doudna access to the synchrotron at Lawrence Berkeley National Laboratory, facilitating her experiments involving high-powered X-ray diffraction.

In 2009, she commenced a leave of absence from Berkeley to assume a leadership role in discovery research at Genentech. However, after a two-month tenure, she departed Genentech and returned to Berkeley, aided by her colleague Michael Marletta, and subsequently cancelled all other commitments to focus on CRISPR research.

As of 2023, Doudna was affiliated with the University of California, Berkeley, where she serves as the director of the Innovative Genomics Institute. This institute, a collaborative venture between Berkeley and UCSF, was established by Doudna with the aim of developing genome editing technology and applying it to address critical societal challenges in human health, agriculture, and climate change. She holds the distinguished Li Ka Shing Chancellor's Professorship in Biomedicine and Health and chairs the Chancellor's Advisor Committee on Biology. Currently, her laboratory's research endeavors concentrate on the structural and functional aspects of CRISPR-Cas systems, the development of novel genome editing technologies and delivery mechanisms for CRISPR therapeutics, and innovative techniques for precise microbiome editing.

Discovery of CRISPR-Cas9 Genome Editing

In 2006, Jillian Banfield introduced Doudna to CRISPR, having located her through a Google search for "RNAi and UC Berkeley," which prominently displayed Doudna's name. Subsequently, in 2012, Doudna and her research team achieved a breakthrough that significantly streamlined the process of genomic DNA editing. This innovation centers on the Cas9 protein, an integral component of the Streptococcus bacterial "CRISPR" immune system, which functions as a molecular scissor in conjunction with guide RNA. Cas9 targets and cleaves viral DNA, thereby inhibiting viral infection of the bacterium. While Yoshizumi Ishino and his collaborators initially identified this system in 1987, and Francisco Mojica subsequently characterized it, Doudna and Emmanuelle Charpentier were the first to demonstrate its programmability using various RNAs for precise DNA cutting and editing.

With the expanding application of CRISPR in multicellular organism editing, Doudna has consistently been recognized as a prominent voice regarding the ethical implications of modifying organismal functions through CRISPR technology. Numerous research groups have subsequently advanced this discovery, leading to diverse applications spanning fundamental cell biology, plant and animal studies, and therapeutic interventions for conditions such as sickle cell anemia, cystic fibrosis, Huntington's disease, and HIV. Doudna, alongside other distinguished biologists, advocated for a global moratorium on the clinical implementation of CRISPR-based gene editing. She endorses the application of CRISPR for somatic gene editing, which involves genetic modifications not inherited by subsequent generations, but opposes its use in germline gene editing.

The advent of the CRISPR system, offering a novel and direct method for DNA editing, precipitated a rapid pursuit of patent protection for the technique. Both Doudna's team at UC Berkeley and a research group at the Broad Institute, associated with the Massachusetts Institute of Technology and Harvard, filed patent applications. Notably, Feng Zhang of the Broad Institute demonstrated the efficacy of CRISPR-Cas9 in editing genes within cultured human cells merely months after Doudna and Charpentier's publication of their methodology. Prior to the resolution of the UC Berkeley patent application, a patent was awarded to the Broad Institute investigators, prompting UC Berkeley to initiate legal action challenging this decision. In 2017, the court ruled in favor of the Broad Institute, which asserted prior initiation of the research and demonstrated the first application of the technology to human cell engineering, providing empirical support for human cell editing, whereas the UC Berkeley group had only proposed this application. UC Berkeley subsequently appealed, contending that their initial disclosures explicitly detailed the methodology for the application later pursued by the Broad Institute. The appeals court affirmed the Broad Institute's patent in September 2018. Concurrently, a patent covering the general CRISPR technique was also granted to UC Berkeley and its co-applicants. Further complicating the patent landscape, the Broad Institute's claim of research precedence was rejected in Europe. This rejection stemmed from a procedural irregularity concerning discrepancies in personnel listed across the lawsuit and patent application, fostering speculation that the UC Berkeley group might ultimately succeed in Europe. In 2011, Doudna co-founded Caribou Biosciences, a company established to commercialize CRISPR technology. Despite ongoing legal disputes, Doudna co-founded Editas Medicine with Zhang and other collaborators in September 2013, though she departed in June 2014; Charpentier subsequently extended an invitation for her to join CRISPR Therapeutics, which Doudna declined, citing her challenging experience at Editas. Additionally, Doudna is a co-founder of Intellia Therapeutics, a spin-off from Caribou, and Scribe Therapeutics, which developed CasX, a more compact, advanced Cas9 variant capable of efficient DNA cleavage.

In 2017, Doudna co-authored A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution with Samuel H. Sternberg. This publication represents a notable instance of a first-person narrative detailing a significant scientific advancement, specifically tailored for a general audience.

Beyond her contributions to the CRISPR breakthrough, Doudna identified an unconventional mechanism employed by the hepatitis C virus for synthesizing viral proteins. This research holds potential for the development of novel antiviral therapies capable of inhibiting infections without inducing tissue damage.

Doudna expressed considerable optimism regarding CRISPR's potential to address untreated genetic diseases and enhance sustainable agriculture, while simultaneously voicing apprehension that the technology's advantages might not extend to the most vulnerable populations without careful and deliberate development.

Mammoth Biosciences

In 2017, Doudna co-established Mammoth Biosciences, a bioengineering technology startup headquartered in San Francisco. The company secured an initial funding of $23 million, followed by a Series B funding round in 2020 that raised an additional $45 million. This enterprise aims to enhance the accessibility of biosensing tests designed to confront challenges in healthcare, agriculture, environmental monitoring, and biodefense.

COVID-19 Response

Commencing in March 2020, Doudna, alongside Dave Savage, Robert Tjian, Fyodor Urnov, Patrick Hsu, and other colleagues at the Innovative Genomics Institute (IGI), spearheaded an initiative to deploy CRISPR-based technologies against the COVID-19 pandemic, concurrently establishing a dedicated testing center. This facility processed more than 500,000 patient samples from UC Berkeley students, staff, faculty, the local community, and agricultural workers in the Salinas region. Concurrently, Mammoth Biosciences reported a peer-reviewed validation of a rapid, CRISPR-based point-of-need COVID-19 diagnostic, which offers advantages in speed and cost efficiency compared to qRT-PCR based assays.

Other Professional Engagements

Doudna serves as the founder and chair of the governance board for the Innovative Genomics Institute, an organization she co-founded in 2014. Her affiliations also include roles as a faculty scientist at Lawrence Berkeley National Laboratory (LBNL), a senior investigator at the Gladstone Institutes, and an adjunct professor of cellular and molecular pharmacology at the University of California, San Francisco (UCSF). In 2025, the National Energy Research Scientific Computing Center at LBNL announced the development of a new supercomputer, named in Doudna's honor, which is slated to succeed the Perlmutter supercomputer.

Doudna holds positions on the scientific advisory boards of companies she co-founded, including Caribou, Intellia, Mammoth, and Scribe, in addition to serving on the boards of Altos Labs, Isomorphic Labs, Johnson amp Johnson, Synthego, Tempus AI, and the Welch Foundation. In 2022, she became the chief science advisor for Sixth Street Partners, where she provides guidance on investment strategies pertaining to CRISPR technology.

Personal Life

Doudna's initial marriage occurred in 1988 to Tom Griffin, a fellow graduate student at Harvard, though their union concluded in divorce several years thereafter. Griffin's desire to relocate to Boulder, Colorado, coincided with Doudna's interest in collaborating with Thomas Cech. While serving as a postdoctoral researcher at the University of Colorado, Doudna encountered Jamie Cate, then a graduate student. Their collaborative efforts focused on crystallizing and elucidating the structure of the Tetrahymena Group I intron P4-P6 catalytic region. Doudna subsequently brought Cate to Yale, and they were married in Hawaii in 2000. Cate later assumed a professorship at the Massachusetts Institute of Technology, and Doudna followed him to Harvard in Boston. However, in 2002, both accepted faculty appointments at Berkeley and relocated there jointly. Cate favored the more informal academic atmosphere of the West Coast, influenced by his prior experiences at the University of California, Santa Cruz, and the Lawrence Berkeley National Laboratory, while Doudna appreciated Berkeley's status as a public university. Currently, Cate is a professor at Berkeley, engaged in research on gene-editing yeast to enhance cellulose fermentation for biofuel generation. Doudna and Cate have a son, born in 2002, who is presently pursuing studies in electrical engineering and computer science at UC Berkeley. The family resides in Berkeley.

Awards and Honors

Doudna was recognized as a Searle Scholar and was granted the 1996 Beckman Young Investigators Award. In 2000, she received the Alan T. Waterman Award, the National Science Foundation's premier accolade for exceptional researchers under 35, in recognition of her work on ribozyme structure determination. The following year, 2001, she was honored with the Eli Lilly Award in Biological Chemistry from the American Chemical Society (ACS).

In 2015, in conjunction with Emmanuelle Charpentier, she was awarded the Breakthrough Prize in Life Sciences for her significant contributions to CRISPR/Cas9 genome editing technology. The following year, in 2016, she received the Canada Gairdner International Award alongside Charpentier, Feng Zhang, Philippe Horvath, and Rodolphe Barrangou. Additionally in 2016, she was honored with the Heineken Prize for Biochemistry and Biophysics. Her other accolades include co-recipient status for the Gruber Prize in Genetics (2015), the Tang Prize (2016), the Japan Prize (2017), and the Albany Medical Center Prize (2017). In 2018, Doudna received the NAS Award in Chemical Sciences, the Pearl Meister Greengard Prize from Rockefeller University, and a Medal of Honor from the American Cancer Society. Also in 2018, she was jointly awarded the Kavli Prize in Nanoscience with Emmanuelle Charpentier and Virginijus Šikšnys. In 2019, she received the Harvey Prize of the Technion/Israel for the 2018 cycle, shared with Emmanuelle Charpentier and Feng Zhang, and the LUI Che Woo Prize in the Welfare Betterment category. In 2020, she was a joint recipient of the Wolf Prize in Medicine with Emmanuelle Charpentier. Later that year, Doudna and Charpentier were awarded the Nobel Prize in Chemistry for their pioneering work in developing a method for genome editing. In 2025, she received the National Medal of Technology and Innovation and was designated to receive the 2026 Priestley Medal from the ACS. Her election to the National Academy of Engineering occurred in 2026.

She gained membership in the National Academy of Sciences in 2002, the American Academy of Arts and Sciences in 2003, the National Academy of Medicine in 2010, and the National Academy of Inventors in 2014. In 2015, alongside Charpentier, she was inducted as a fellow of the American Academy of Microbiology. Her distinction as a Foreign Member of the Royal Society (ForMemRS) was conferred in 2016. In 2017, Doudna received the Golden Plate Award from the American Academy of Achievement. In 2020, she was awarded a Guggenheim Fellowship. The year 2021 saw her receive the Award for Excellence in Molecular Diagnostics from the Association for Molecular Pathology. Also in 2021, Pope Francis appointed Doudna, along with fellow Nobel laureates Donna Strickland and Emmanuelle Charpentier, as members of the Pontifical Academy of Sciences.

In 2015, she and Charpentier were recognized as among the Time 100 most influential individuals. Subsequently, in 2016, she was a runner-up for Time Person of the Year, sharing this distinction with other CRISPR researchers. In 2018 and 2023, she was conferred honorary Doctor of Science degrees by USC and Harvard, respectively.

Busch-Vishniac, Ilene; Busch, Lauren; Tietjen, Jill (2024). "Chapter 50: Emmanuelle Charpentier and Jennifer Doudna." In Women in the National Inventors Hall of Fame: The First Fifty Years. Springer Nature. ISBN 9783031755255.